bullish
Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging
144 Views11 Apr 2017 09:07
We are raising our fair value estimate to AUD 2.80 per share from AUD 2.30 for no-moat Mesoblast Ltd (MSB AU), following the encouraging interim...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 58-minute read)
Discussions
(Paid Plans Only)
Morningstar, Inc.
Leading Independent Investment Research
Price Chart(Sign Up to Access)
- Raising FVE for Mesoblast After Adjusting for AUD as We Await 180 Day Survival Data in AGvHD13 Jul 2018
- Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric AGvHD01 Mar 2018
- Current Share Price Ascribes No Value to Chronic Heart Failure Potential, but Risk Still Very High24 May 2016
- Mesoblast's Partner Receives Full Approval in Japan; Commercial Launch Ahead21 Sep 2015
- Major Milestone Ahead for Mesoblast as Japanese Partner Moves Closer to Market with JR-03108 Sep 2015
x